Consensus report of the 2021 National Cancer Institute neuroendocrine tumor clinical trials planning meeting.

Autor:	Singh S; Department of Medicine, Sunnybrook Health Sciences Centre, Odette Cancer Center, University of Toronto, Toronto, ON, Canada., Hope TA; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA., Bergsland EB; Department of Medicine, University of California, San Francisco, CA, USA., Bodei L; Department of Radiology, Memorial Sloan Kettering Cancer Center, Molecular Imaging and Therapy Service, New York, NY, USA., Bushnell DL; Department of Radiology, University of Iowa, Iowa City, IA, USA., Chan JA; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chasen BR; Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chauhan A; Department of Medicine, University of Miami Sylvester Comprehensive Cancer Center, Miami, FL, USA., Das S; Late-Stage Development, Oncology R&D AstraZeneca, Gaithersburg, MD, USA., Dasari A; Department of GI Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Del Rivero J; Developmental Therapeutics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., El-Haddad G; Department of Diagnostic Imaging and Interventional Radiology, Moffitt Cancer Center, Tampa, FL, USA., Goodman KA; Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, USA., Halperin DM; Department of GI Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Lewis MA; Department of Medicine, Intermountain Health, Salt Lake City, UT, USA., Lindwasser OW; Coordinating Center for Clinical Trials, National Cancer Institute, Bethesda, MD, USA., Myrehaug S; Department of Radiation Oncology, Sunnybrook Health Sciences Centre, Odette Cancer Center, Toronto, ON, Canada., Raj NP; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Reidy-Lagunes DL; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Soares HP; Department of Medicine, Huntsman Cancer Institute at University of Utah, Salt Lake City, UT, USA., Strosberg JR; Department of Gastrointestinal Oncology, Moffitt Cancer Center, Tampa, FL, USA., Kohn EC; National Cancer Institute, Bethesda, MD, USA., Kunz PL; Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.
Jazyk:	angličtina
Zdroj:	Journal of the National Cancer Institute [J Natl Cancer Inst] 2023 Sep 07; Vol. 115 (9), pp. 1001-1010.
DOI:	10.1093/jnci/djad096
Abstrakt:	Important progress has been made over the last decade in the classification, imaging, and treatment of neuroendocrine neoplasm (NENs), with several new agents approved for use. Although the treatment options available for patients with well-differentiated neuroendocrine tumors (NETs) have greatly expanded, the rapidly changing landscape has presented several unanswered questions about how best to optimize, sequence, and individualize therapy. Perhaps the most important development over the last decade has been the approval of 177Lu-DOTATATE for treatment of gastroenteropancreatic-NETs, raising questions around optimal sequencing of peptide receptor radionuclide therapy (PRRT) relative to other therapeutic options, the role of re-treatment with PRRT, and whether PRRT can be further optimized through use of dosimetry among other approaches. The NET Task Force of the National Cancer Institute GI Steering Committee convened a clinical trial planning meeting in 2021 with multidisciplinary experts from academia, the federal government, industry, and patient advocates to develop NET clinical trials in the era of PRRT. Key clinical trial recommendations for development included 1) PRRT re-treatment, 2) PRRT and immunotherapy combinations, 3) PRRT and DNA damage repair inhibitor combinations, 4) treatment for liver-dominant disease, 5) treatment for PRRT-resistant disease, and 6) dosimetry-modified PRRT. (© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu